What is RxGenomix?
RxGenomix operates at the intersection of biotechnology and clinical practice, specializing in the ExactMeds pharmacogenomic service. The company utilizes advanced genetic profiling to provide tailored medication recommendations, effectively mitigating the risks associated with adverse drug events. By serving a multifaceted client base—ranging from individual patients managing chronic conditions to large-scale enterprise employers—RxGenomix optimizes healthcare delivery through data-driven insights. Their platform integrates seamlessly into existing clinical workflows, offering population analytics and practice integration tools that enhance therapeutic efficacy and reduce overall healthcare expenditures. As the industry shifts toward value-based care, the company's ability to translate complex genomic data into actionable clinical intelligence positions it as a critical partner for providers and payers alike.
How much funding has RxGenomix raised?
RxGenomix has raised a total of $318K across 2 funding rounds:
Debt
$150K
Debt
$168K
Debt (2020): $150K with participation from PPP
Debt (2021): $168K led by PPP
Key Investors in RxGenomix
PPP
Public-Private Partnership
What's next for RxGenomix?
With this recent capital, RxGenomix is expected to accelerate its enterprise-level expansion and deepen its investment in population health analytics. The strategic focus will likely center on broadening the reach of its ExactMeds platform, enhancing the scalability of its genetic testing services, and fostering deeper integration with healthcare provider networks. As the firm navigates this late-stage growth phase, the emphasis will remain on demonstrating long-term clinical utility and cost-saving potential for its corporate and institutional partners. By refining its proprietary algorithms and expanding its clinical footprint, RxGenomix aims to set a new standard for medication safety and personalized treatment protocols in the modern healthcare landscape.
See full RxGenomix company page
